EMPOWERPHARM
LIVE

Serial Number

97092446

Owner

EmpowerPharm Inc.

Attorney

Nicole K. McLaughlin

Filing Date

Oct 26, 2021

Add to watchlist:

No watchlists yet
View on USPTO

EMPOWERPHARM Trademark

Serial Number: 97092446

EMPOWERPHARM is a trademark filed by EmpowerPharm Inc. on October 26, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

EmpowerPharm Inc. (8 trademarks)

Suite 603
Burlington, Ontario L7L6M1 , CA

Entity Type: 03

Trademark Details

Filing Date

October 26, 2021

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations containing synthetic cannabidiol (CBD) for the treatment of various diseases, conditions and disorders; Pharmaceutical preparations containing synthetic cannabidiol (CBD) for the treatment of anxiety, stress, pain and insomnia; Pharmaceutical preparations containing synthetic cannabidiol (CBD) for the treatment of anxiety; Natural health products, namely, glucosamine, turmeric supplements, dietary supplements to aid digestion, melatonin, sleep support supplements, fish oils, probiotics in tablet, capsule, gummy vitamin and liquid form; vitamin supplements; mineral supplements; vitamin and mineral food supplements; vitamin and mineral dietary supplements; vitamin preparations; mineral preparations; multivitamins; prenatal vitamins; calcium supplements; nutritional supplements for general health and well-being, namely, magnesium in tablets, capsules, gummies, and liquids; dietary supplements for promoting weight loss; over the counter medications for treating aches, pains, headaches, arthritis pain, sprains, and for treatment of minor joint injuries and muscle soreness, nonsteroidal anti-inflammatory drugs (NSAIDs), ibuprofen, naproxen sodium, acetaminophen, cold, sore throat and cough medications, guaifenesin, liquid cough medicines with dextromethorphan, decongestant nasal sprays, pseudoephedrine, phenylephrine, allergy medications, antihistamine pills and liquids, diphenhydramine, chlorpheniramine, brompheniramine, loratadine, fexofenadine, cetirizine, stomach upset medications, namely, probiotic preparations for medical purposes to help maintain a natural balance of flora in the digestive system, antidiarrhea medicines, loperamide, bismuth, nausea treatment preparations, pharmaceutical preparations for the treatment of vomiting and motion sickness, dimenhydrinate; cannabidiol (CBD) oil for medical purposes; cannabidiol (CBD) for medical purposes; cannabidiol (CBD) for medical purposes in the form of suppositories, sublingual doses that dissolve in the mouth, creams, ointments, and doses for absorption in the mucous membranes; tablets, capsules, gummies, suppositories, skin patches, sublingual doses, extended release tablets and liquids for therapeutic purposes containing cannabidiol (CBD); herbal supplements containing cannabidiol (CBD); Liquid nutritional supplement containing cannabidiol (CBD) for treating, reducing or improving symptoms of various conditions, namely, pain, anxiety, depression, cancer, acne, skin conditions, neuroprotection, cardiovascular health, arthritis, inflammation, autoimmune conditions, epileptic seizures, nausea, appetite, inflammatory bowel disease, and insomnia; tetrahydrocannabinol (THC) for medical purposes; tetrahydrocannabinol (THC) for medical purposes in sublingual doses and doses for absorption in the mucous membranes; tablets, capsules, gummies, suppositories, skin patches, sublingual doses, extended release tablets and liquid for therapeutic purposes containing tetrahydrocannabinol (THC) and containing a combination of tetrahydrocannabinol (THC) together with cannabidiol (CBD)

Filing History

NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 16, 2026 GNRN
NON-FINAL ACTION E-MAILED
Apr 16, 2026 GNRT
NON-FINAL ACTION WRITTEN
Apr 16, 2026 CNRT
ASSIGNED TO EXAMINER
May 2, 2023 DOCK
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 20, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 20, 2022 TCCA
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 20, 2022 COAR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 9, 2021 NWOS
NEW APPLICATION ENTERED
Oct 29, 2021 NWAP